With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Following the discussion, attendees will have the opportunity to participate in a live Q&A session, further addressing ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...